{"id":39256,"date":"2020-10-11T07:30:41","date_gmt":"2020-10-11T07:30:41","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=39256"},"modified":"2020-11-26T13:17:53","modified_gmt":"2020-11-26T13:17:53","slug":"oxford-covid-vaccine-enrols-hiv-positive-poeple-at-two-london-sites","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/39256","title":{"rendered":"Oxford COVID vaccine enrolling HIV positive people at two London sites"},"content":{"rendered":"
\n

UPDATE: Please note that enrolment is now complete for both study sites. Thanks to everyone that helped by joining. Information about future studies will also be included in HTB.<\/strong><\/p><\/em><\/div>\n\n

<\/strong><\/span><\/p>\n

Simon Collins, HIV i-Base<\/strong><\/span><\/p>\n

The much publicised vaccine being developed at Oxford University has just added a new substudy group to the main trial that will look at immune responses in people living with HIV.<\/span><\/strong><\/p>\n

The main study is randomising 20,000 participants to either an active vaccine or a control group (using a vaccine against meningitis). Initial restricted entry has steadily been expanded to include people who are older and who have other specific criteria. However, the current trial listing on either ClinicalTrials.gov or the Oxford University website does not yet reference the HIV study. [1, 2]<\/p>\n

The HIV study (referred to as Group 12) will enrol 60 HIV positive adults but will not include a control group. This means that all participants will get the active vaccine. The study will last for a year and involve about 12 clinic visits.<\/p>\n

Also, unlike the main study, the HIV substudy includes compensation for time and travel up to \u00a3550 (for all visits).<\/p>\n

The HIV study will be run from two London sites, St Mary’s and Guys and St Thomas\u2019, both with HIV expertise.<\/p>\n

Inclusion criteria include:<\/p>\n

\n